Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharma to acquire 45% stake in Canadian venture for pharma market expansion
Alembic Pharmaceuticals enters a Canadian joint venture with a 45% stake as it looks to strengthen its global pharma footprint. Alembic Pharmaceuticals shares closed at ₹742.75 on the NSE, up ₹5.20 or 0.71%.
Alembic Pharma receives USFDA approval for Haloperidol tablets
Alembic Pharmaceuticals announced that it has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Haloperidol Tablets USP in strengths of 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
Alembic Pharmaceuticals receives USFDA approval for Haloperidol Tablets
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
Alembic Pharmaceuticals to attend Trinity India 2026 conference - scanx.trade
Alembic Pharmaceuticals to attend Trinity India 2026 conferencescanx.trade
Alembic gets USFDA nod for generic levothyroxine sodium tablets
Alembic Pharmaceuticals has secured final approval from the US health regulator for its generic levothyroxine sodium tablets. This medication is used as a replacement therapy for hypothyroidism. The approval covers multiple strengths of the tablets. This development is significant for patients seeking affordable treatment options. The market for these tablets is substantial.
Alembic Pharma gets USFDA nod for thyroid disorder and cancer treatment drug
Alembic Pharmaceuticals gets USFDA nod for Levothyroxine Sodium Tablets, used as replacement therapy for congenital or acquired hypothyroidism and are also indicated as an adjunct treatment in certain thyroid cancer cases. This boosts Alembic Pharma's ANDA tally to 239.
Alembic Pharmaceuticals receives USFDA approval for Levothyroxine Sodium Tablets
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg.
Alembic Pharmaceuticals consolidated net profit rises 29.20% in the March 2026 quarter
Sales rise 4.41% to Rs 1847.72 crore
Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend
The company also recommended a dividend of ₹12 per equity share of face value ₹2 each for shareholders. Shares of Alembic Pharmaceuticals Ltd ended at ₹782.10, down by ₹4.35, or 0.55%, on the BSE.
Alembic Pharma gains after Q4 PAT climbs 29% YoY to Rs 203 cr
Alembic Pharmaceuticals rose 1.11% to Rs 795.20 after the company's consolidated net profit jumped 29.19% to Rs 202.70 crore in Q4 FY26, compared to Rs 156.89 crore posted in Q4 FY25.
Q4 Results LIVE Updates: JSW Steel, Muthoot react to results; Tata Steel, Power Grid report today
Q4 Results LIVE Updates: Two Nifty 50 companies Tata Steel and Power Grid along with broader market names like ITC Hotels, Hindustan Copper, Godfrey Phillips, Gland Pharma, Cochin Shipyard, Deepak Nitrite, Balrampur Chini, Arvind, Bajaj Electricals, Aarti Drugs, Aether Industries, Alembic Pharma, NCC, NHPC, Premier Energies, SAIL, SJVN, Solara Active Pharma, Symphony, Thangamayil, Triveni Engineering, VST Tillers, are among the companies reporting their earnings today. JSW Steel, Muthoot Finance, Apollo Tyres, Endurance Tech, Voltas, are some of the other result reactions today. Watch this space for all the LIVE updates.
Alembic Pharma gets USFDA tentative nod for generic prostate cancer drug
Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic version of Darolutamide tablets, targeting prostate cancer treatment. The approval is for the 300 mg strength. The drug is a generic version of Nubeqa Tablets. The robust market potential for these tablets suggests promising future growth for Alembic.